



PLATINUM INT'L HEALTH CARE FUND ARSN 107 023 530

E	/	١,	С	T	S

\$70.58 mn Portfolio Value Fund commenced 10 November 2003

A\$20,000 or NZ\$25,000 Minimum investment A\$200 or NZ\$250 per mth/qtr Regular Investment Plan (min.)

Income distribution date Unit valuation

Annual, 30 June Sydney Business Day

App 1.5405 Red 1.5328 Unit prices

F	Ε	ES

Entry fee Nil Exit fee Nil

Management Expense Ratio/ 1.54% per annum Indirect Cost Ratio (MER/ICR) (inclusive of investment &

administration costs)

Brokerage paid

Buy/sell spread 0.5% total

PERFORMANCE ¹					
	FUND %	MSCI %			
1 month	8.46	7.74			
3 months	18.82	20.62			
6 months	24.44	34.28			
Calendar year to date	32.14	43.04			
1 year	44.81	53.48			
2 years (compound pa)	25.14	32.30			
3 years (compound pa)	21.44	21.57			
5 years (compound pa)	13.51	11.13			
7 years (compound pa)	8.35	5.17			
Since inception (compound pa)	7.36	6.24			

INVESTED POSITION ³					
	LONG %	NET %	CURRENCY %		
Australia	2.0	2.0	4.8		
Belgium	2.4	2.4			
Brazil	1.7	1.7	1.7		
Denmark	4.1	4.1	4.1		
France	5.4	5.4			
Germany	5.7	5.7			
Italy	4.8	4.8			
Japan	3.4	3.4	3.1		
Sweden	4.3	4.3	4.3		
Switzerland	10.0	10.0	10.0		
UK	7.0	7.0	7.1		
US	27.2	25.1	35.4		
Total	78.0	75.9			
Canadian \$			2.0		
Euro			22.1		
HK\$			2.3		
Norwegian Krone			1.2		
Singapore \$			1.9		
Cash & Accruals	22.0	24.1	_		
Total	100.0	100.0	100.0		
Long - 48 stocks Short - 1 index					

1. Investment returns are calculated using the Fund's unit price and represent the combined income and capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns can be negative (particularly in the short-term).

De negative (particularly in the short-term).

2. The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund since inception relative to the MSCI All Country World Health Care Net Index in A\$.

The investment returns are calculated using the Fund's unit price.

They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through

Platinum's individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only.

3. The "Long %" represents the exposure of physical holdings and long stock derivatives. The "Net %"

represents the exposure of physical holdings and both long and short derivatives. The "Currency %" represents the currency exposure for the Fund's Portfolio, taking into

account currency hedging.

4. Top Ten positions shows the Fund's top long share exposure positions. Long derivative exposures are included, however, short derivative exposures are not.

PERFORMANCE GRAPH ²					
\$45,000		Platinum In	t'l Health (Care Fun	d
\$40,000 -		99.3 %			
\$35,000 -					
\$30,000 -				ل ا	"
\$25,000 -	مر.۵	KAN I	M.A.	رمم	,
\$20,000 -		MSC	I AC World		Care 0.1%
\$15,000	-				
20	03 200	5 2007	2009	2011	2013

Source: Factset and Platinum

l	TOP TEN POSITIONS"					
	<u>STOCK</u>	COUNTRY	<u>INDUSTRY</u>	<u>%</u>		
l	Sanofi SA	France	Pharmaceuticals	3.0		
l	Teva Pharmaceuticals	United States	Pharmaceuticals	3.0		
l	Novartis AG	Switzerland	Pharmaceuticals	2.8		
l	Alere Inc	United States	Health Equip & Servs	2.7		
l	Qiagen NV	Germany	Health Equip & Servs	2.7		
l	Ipsen SA	France	Pharmaceuticals	2.4		
l	Roche Holding AG	Switzerland	Pharmaceuticals	2.3		
l	AstraZeneca PLC	United Kingdom	Health Equip & Servs	2.2		
l	Immunogen Inc	United States	Biotechnology	2.2		
l	Pfizer Inc	United States	Pharmaceuticals	2.2		

INDUSTRY BREAKDOWN ³		
SECTOR	LONG %	NET %
Pharmaceuticals	41.2	41.2
Health Equipment & Services	14.1	14.1
Biotechnology	11.6	11.6
Healthcare Providers	3.7	3.7
Misc Manufacturing	3.6	3.6
Electrical Equipment	2.0	2.0
Chemicals	1.8	1.8
Equity Funds*		(2.1)
*Includes index short position		

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management (Platinum) is the responsible entity and issuer of units in the Platinum Int'l Health Care Fund (the Fund). The Platinum Trust Product Disclosure Statement No.8 and Supplementary PDS (together PDS) provides details about the Fund. You can obtain a copy of the PDS from Platinum's website, www.platinum.com.au, or by contacting Investor Services on 1300 726 700 (Australian investors only), 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via Invest@platinum.com.au

Before making any investment decision you need to consider (with your financial adviser) your particular investment needs, objectives and financial circumstances. You should refer to the

DISCLAIMER: The information presented in this fact Sheet is not intended to be advice. Tou Should refer to the DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Platinum does not surrantee the repayment of capital navment of income or the Fund's performance. guarantee the repayment of capital, payment of income or the Fund's performance. Platinum is a member of the Platinum Group of companies.